PhenoVista Biosciences

We are pleased to announce our growth capital raise from BroadOak Capital Partners! This investment will enable us to accelerate our growth by continuing to invest in our passion: providing our clients with data from cutting-edge cell models not available from any other service provider. https://bwnews.pr/3GGLMgI #highcontentscreening #investment

We're excited to participate in Bio Partnering at #JPM2022 starting today,...looking forward to connecting with fellow attendees! #healthcarepartneringweek #jpmweek https://www.bio.org/events/bio-partnering-jpm

We are excited about our strategic partnership with FUJIFILM Cellular Dynamics (FCDI)! The partnership combines FCDI’s portfolio of human induced pluripotent stem cells (hiPSC) with PhenoVista’s drug discovery and assay-development services to develop applications of new FCDI products and offer US-based, custom analytical services to advance drug-discovery technologies using hiPSC models. To learn more: https://bit.ly/3n6P7xD #highcontentscreening #ipsc #cellbiology #pharma

Join us next week for a joint webinar with our partners at Yokogawa Life Science! We will describe how we use their Benchtop CQ1 Confocal System to generate translatable high-content imaging data from physiologically-relevant cell models, including 3D structures. https://www.linkedin.com//applicationsofhigh-contentimagi/

As we reflect back on the successes and challenges of 2021 here at PhenoVista and look forward to the next year, we want to wish you and yours a safe and happy 2022. Here's to good data and great images! Happy New Year!! The PhenoVista Team

We are honored that the National Institutes of Health (NIH) is providing a $250K Phase 1 SBIR Grant to support our program to develop phenotypic screening assays using iPSC-derived microglia in neuronal models of Alzheimer's Disease! #Alzheimers #SBIR #NIH Link to Press Release: https://phenovista.com/post-1189/

Our #Yokogawa CQ1 Benchtop High-Content Analysis System is installed and currently being used to capture beautiful images like these! Here, we see adipocytes differentiated into brown fat and stained to highlight their lipid droplets (Green=BODIPY), mitochondria, (Red=MitoTracker) and nuclei (Blue=Hoescht). The CQ1 is also compatible with 3D imaging of organoids, spheroids and tumor fragments. Contact us today to learn more! https://phenovista.com/contact-us/ #highcontentscreening #adipocytes

Are you attending #SLAS2021? Our CEO, James Evans will be speaking at the Phenotypic Drug Discovery special interest group and Ray Price will be hosting the Technology Transfer and CRO/CMO special interest group (details below). Make sure to register so that you won’t miss us! Link: https://www.eventscribe.net/2021/SLAS2021/

Are you using @ScienceExchange for your 2021 projects? This popular outsourcing platform makes it fast and easy to work with us. We’re part of the Science Exchange Contracted Provider Network, which means we can get to work on your project immediately; no need for additional CDAs, MTAs or other time-consuming legal documents. Current customers thanks for your business, please leave us an endorsement! Visit our Science Exchange profile, https://www.scienceexchange.com/labs/phenovista-biosciences and join the scientists using this online platform to boost their productivity.

If you’re attending #JPM2021 today, be sure to chat with our VP of Business Development, Ray Price! He’s looking forward to connecting with fellow attendees. #healthcarepartneringweek #jpmweek https://lnkd.in/eSt7Mu4

Check out this article from @SelectScience where our CEO James Evans explains how Phenovista helps other drug discovery companies grow and succeed following scientific collaboration, sharing ideas, and teaming up to win! #drugdiscovery https://www.selectscience.net//helping-scientists-succee/

Phenovista’s #Halloween2020 Party had some unusual guest appearances, including Between Two Ferns Host Zach Galafinakis, Uncle Rico, and Elizabeth Holmes! Who else can you spot? #spookyscientists

We’re all engaging in #neuroscience discussions in a different way this year and thank you for following along virtually this week! In this neuro-themed study, PV scientists examined the effect of CCCP on #mitochondrial membrane potential and function in neurons. What differences can you spot in these images? #Neuroscience #mitochondria #microscopy

At PhenoVista, we have the capability to perform neuronal network analysis by imaging and colocalizing pre- and post-synaptic markers. These images show the analysis of synapse formation in long-term cultures of Human iPS-derived neurons.

While the community regrets and supports the cancellation of SfN 2020, PhenoVista would like to dedicate this week to neuroscience and share some of the neurosphere antibody staining and masking we have performed in collaboration with StemoniX. These figures show the localization of the astrocytic maker GFAP throughout a neurosphere and our ability to image and segment the nuclei in neurospheres from a maximum intensity projection using the nuclear marker DRAQ5.

Tomorrow is World #CRISPR Day, a celebration of the powerful gene editing technique highlighted by the recent #NobelPrize award. Here we utilized CRISPR gene knockout in a tumor cell line to assess phenotypic changes in cell health and morphology using an unbiased approach called #CellPainting. Masking for Target antibody-negative cells (indicated by colored overlay) allows for quantification of changes in Cell Painter dyes of knockout vs WT cells within the same well. https://crisprmedicinenews.com//world-crispr-day-october-/

As part of our ongoing partnership with Champions Oncology we are excited to participate in the upcoming Ex Vivo Screen for Adult & Pediatric Sarcoma, including 56 unique PDX tumor across a wide range of subtypes. The Champions PDX models are extensively characterized with clinical annotation and NGS data as well as data on in vivo and patient responses to standards of care. For more information on the screen visit the Champions website. https://www.championsoncology.com/ex-vivo-screen-for-adult-

Join us this week for a free #webinar hosted by our partners at Olympus Life Sciences. Our CEO James Evans will be presenting on how NoviSight 3D analysis software helps us quantify phenotypic changes in 3D tumor models and organoids. Register today - https://www.labmanager.com//applications-of-advanced-image

We're #hiring immediately for several open RA positions. Would you like to join our team, or do you know anyone who would be a good fit? Job link is here: https://www.linkedin.com/jobs/view/2183085917/ #cellpainting #highcontentscreening #cellculture

At PhenoVista we engage with clients in a highly collaborative and flexible manner. Most projects involve completely integrated workflow, from cell biology through test article treatment, high content image acquisition, and analysis to generate actionable data. We can also add value to clients who have challenges with specific parts of the assay development and execution process, including assay development/ transfer and in silico analysis of images. To learn more, visit our website: https://phenovista.com/styles-of-engagement/ #highcontent #microscopy

Today is Metastatic Breast Cancer Awareness Day, and all of October is National Breast Cancer Awareness Month. One driver of many breast cancers is disruption of the normal DNA damage response (DDR), which can be exploited as an Achilles’ heel by certain therapeutic agents such as PARP inhibitors. Here we show induction of DDR in tumor cells in response to etoposide. https://nationaltoday.com/metastatic-breast-cancer-awarene/ #breastcancerawareness

PhenoVista would like to celebrate the 5-year anniversary of our Senior Laboratory Manager Erika Martin. As the first employee (after the founders), Erika’s extensive experience in imaging and stem cell biology adds value to our clients. In addition to heroic management of the 3-ring circus that is a growing biotech company, her sunny personality (and coordination of donut deliveries) makes PhenoVista a fun place to work!

PhenoVista would like to congratulate Emmanuelle Charpentier and Jennifer Doudna, recipients of the 2020 Nobel Prize in Chemistry for their work on CRISPR. This powerful genome editing technique has quickly become a mainstay of functional genomics and has the potential to dramatically impact human health and the environment. Here we collaborated with Synthego to utilize CRISPR gene knockout of a target in a tumor cell line to assess phenotypic changes in cell health and morphology using a modified Cell Painting approach. https://www.nobelprize.org/prizes/chemistry//press-release/ #CRISPR #Synthego